The San Antonio Breast Cancer Symposium is starting next week, and it will bring plenty of presentations of breakthrough research on cancer and chemotherapy combinations. This includes the findings of a ten-year study on the benefits of medications like herceptin, doxorubicin, docetaxel and carboplatin.
The Symposium Will Focus on the Treatment of HER2-Positive Breast Cancer
New data on the efficiency of anthracyclines will be revealed at the symposium, which will verify the safety of its use on patients with HER-2-positive brain cancer. TheS an Antonio Breast Cancer Symposium will also have an oral presentation discussing avelumab, an inhibirot from Pfizer that can help treat this specific kind of breast cancer.
Some Treatments Discussed Have Already Been Approved for Use
Several medications that will be showcased are already in use, such as denosumab, which increases bone mass in breast cancer patients who are undergoing endocrine therapy and are at risk for bone fracture.
The San Antonio Breast Cancer Symposium is looking to reveal how it can help treat the cancer in addition to aiding in bone-building.
